Search research articles
Contact Us
Filters
Showing results (11-20 of 69) with videos related to
Page
of 7
Sort By:
Lancet (London, England)
|
August 15, 2006
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
Gilles R Dagenais, Janice Pogue, Kim Fox, et al.
Lancet (London, England)
|
September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
Kim Fox, Ian Ford, P Gabriel Steg, et al.
Journal of Analytical Toxicology
|
August 23, 2019
Validation of a High-throughput Screening and Quantification Method for the Determination of Gabapentinoids in Blood Using a Combination of LC-TOF-MS and LC-MS-MS
Hilda De La Vega, Kim Fox, Justine Pardi, et al.
European Heart Journal
|
September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
Kim Fox, Ian Ford, Ph Gabriel Steg, et al.
The New England Journal of Medicine
|
September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failure
Kim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal
|
September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study
Kim Fox, Ian Ford, Philippe Gabriel Steg, et al.
American Heart Journal
|
October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure
Kim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal
|
December 28, 2020
Management of refractory angina: an update
Allan Davies, Kim Fox, Alfredo R Galassi, et al.
Circulation. Cardiovascular Quality and Outcomes
|
December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy
Michal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Cardiology
|
August 1, 2012
Cardiac rehabilitation to improve physical functioning in refractory angina: a pilot study
Elizabeth A Asbury, Carolyn M Webb, Heather Probert, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 69) with videos related to
Sort By:
Page
of 7
Lancet (London, England)
|
August 15, 2006
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
Gilles R Dagenais, Janice Pogue, Kim Fox, et al.
Lancet (London, England)
|
September 2, 2008
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
Kim Fox, Ian Ford, P Gabriel Steg, et al.
Journal of Analytical Toxicology
|
August 23, 2019
Validation of a High-throughput Screening and Quantification Method for the Determination of Gabapentinoids in Blood Using a Combination of LC-TOF-MS and LC-MS-MS
Hilda De La Vega, Kim Fox, Justine Pardi, et al.
European Heart Journal
|
September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
Kim Fox, Ian Ford, Ph Gabriel Steg, et al.
The New England Journal of Medicine
|
September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failure
Kim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal
|
September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study
Kim Fox, Ian Ford, Philippe Gabriel Steg, et al.
American Heart Journal
|
October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure
Kim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal
|
December 28, 2020
Management of refractory angina: an update
Allan Davies, Kim Fox, Alfredo R Galassi, et al.
Circulation. Cardiovascular Quality and Outcomes
|
December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy
Michal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Cardiology
|
August 1, 2012
Cardiac rehabilitation to improve physical functioning in refractory angina: a pilot study
Elizabeth A Asbury, Carolyn M Webb, Heather Probert, et al.
Page
of 7